Chuikyo’s Drug Pricing Panel to Continue Discussions on Penalties and Actions against Novartis

JMA Vice President Toshio Nakagawa A panel under the Central Social Insurance Medical Council (Chuikyo), will continue discussing whether to take action against Novartis Pharma K.K. over the possible impact that flawed clinical data on its hypertension drug Diovan (valsartan)...read more